Genetic testing company Natera (NASDAQ:NTRA). reported Q4 CY2024 results , with sales up 53% year on year to $476.1 million.
BTIG analyst Mark Massaro raised the firm’s price target on Natera (NTRA) to $190 from $185 and keeps a Buy rating on the shares. The company ...
A federal judge on Monday threw out a $96 million jury verdict against genetic testing company CareDX that rival Natera had ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for ...
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Natera (NTRA) to $188 from $183 and keeps an Outperform rating on the ...
Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid ...
The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high- ...
In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Natera (NTRA – Research Report), with a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback